Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 154
- Registration Number
- NCT05298592
- Locations
- 🇺🇸
Local Institution - 0021, Birmingham, Alabama, United States
🇺🇸University California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 784
- Registration Number
- NCT05298423
- Locations
- 🇨🇳
Tianjin Cancer Hospital ( Site 0329), Tianjin, Tianjin, China
🇨🇳Hangzhou Cancer Hospital-Medical Oncology ( Site 0302), Hangzhou, Zhejiang, China
🇨🇳The Second Affiliated hospital of Zhejiang University school of medicine ( Site 0301), Hangzhou, Zhejiang, China
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 812
- Registration Number
- NCT05296798
- Locations
- 🇮🇹
Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy
🇵🇱Przychodnia Lekarska KOMED, Roman Karaszewski, Konin, Poland
🇵🇹Hospital de S. Francisco Xavier; Unidade de Oncologia Medica, Lisboa, Portugal
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
- Conditions
- Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Primary Peritoneal Endometrioid AdenocarcinomaRecurrent Fallopian Tube Endometrioid AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Ovarian High Grade Serous Adenocarcinoma
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05295589
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in Patients with Recurrent And/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- NATCO Pharma Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT05283226
- Locations
- 🇺🇸
Providence Medical Foundation -Fullerton, Fullerton, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Lynn Cancer Center, Boca Raton, Florida, United States
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)
- Conditions
- Interventions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 128
- Registration Number
- NCT05281003
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
- Conditions
- Ovarian High Grade Serous AdenocarcinomaUnresectable Fallopian Tube High Grade Serous AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaPrimary Peritoneal Endometrioid AdenocarcinomaPrimary Peritoneal High Grade Serous AdenocarcinomaStage III Primary Peritoneal Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Unresectable Fallopian Tube Endometrioid AdenocarcinomaUnresectable Ovarian Endometrioid AdenocarcinomaUnresectable Ovarian High Grade Serous Adenocarcinoma
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT05276973
- Locations
- 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 66
- Registration Number
- NCT05275777
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)
- Conditions
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 74
- Registration Number
- NCT05267470
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation, Taoyuan, Taiwan
🇺🇸Montefiore Einstein Center for Cancer Care, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.